CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S.
commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the
treatment of rare neuromuscular diseases, granted equity awards on May 31, 2017, that were previously approved by the Compensation
Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to
employment to ten individuals hired by Sarepta in May 2017. The equity awards were approved in accordance with Nasdaq Listing Rule
5635(c)(4).
The employees received, in the aggregate, options to purchase 57,820 shares of Sarepta's common stock. The options
have an exercise price of $29.84 per share, which is equal to the closing price of Sarepta's common stock on May 31, 2017.
One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and
thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option
granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each
such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development
of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly
advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more
information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website
at www.sarepta.com. We encourage investors and potential investors to consult our website
regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 iestepan@sarepta.com or W2O Group Brian Reid, 212-257-6725 breid@w2ogroup.com
